Ryan Bushey
Digital Editor

Ryan Bushey is a digital editor for Advantage Business Media’s Science Group.  He covers scientific discoveries, emerging technologies and the business of the life sciences sector for R&D Magazine and Drug Discovery & Development along with managing social media for both publications. He’s an experienced journalist whose work has appeared in Business Insider, Slate, and Indiewire.

The venture's proprietary platform could identify unique disease targets that can’t be addressed with traditional clinical approaches.
Digital Editor
|
10.20.2017
9:46am
Regeneron will be its sponsor while Aimmune will provide the clinical supply of AR101 and food challenge materials.
Digital Editor
|
10.17.2017
8:50am
Clinical investigators have incorporated these markers into the later stages of clinical trials to assist in reducing sample size and refining the patient...
Digital Editor
|
10.16.2017
11:00am
Some of the companies participating in this effort include AbbVie, Amgen, Celgene Corporation, and Roche.
Digital Editor
|
10.12.2017
11:26am
The product is intended to create a new epilepsy treatment that reduces the number of seizures and enables a faster recovery.
Digital Editor
|
10.10.2017
11:18am
Advertisement
Administration of the medication occurs via a smartphone or similar wireless device.
Digital Editor
|
10.6.2017
10:28am
The dots differ from previous antibiotic treatments because they are able to work selectively on an intracellular level.
Digital Editor
|
10.5.2017
10:30am
One company is working on novel antibiotics that could combat a considerable health crisis.
Digital Editor
|
10.4.2017
11:00am
This data emphasizes how difficult it’s been to launch a new drug for this condition.
Digital Editor
|
9.26.2017
10:10am
Major pharmaceutical companies have encountered considerable difficulties for developing drugs that treat destructive neurological conditions.
Digital Editor
|
9.26.2017
9:02am
A novel therapy could provide some hope in combating a difficult-to-treat symptom of Parkinson’s disease.
Digital Editor
|
9.25.2017
10:20am
The pharmaceutical company plans on submitting a New Drug Application to the FDA in late 2017.
Digital Editor
|
9.20.2017
9:33am
The tool works by measuring immune system biomarkers in blood samples and then uses machine learning algorithms to identify patterns in certain infections.
Digital Editor
|
9.19.2017
9:49am
Advertisement
Findings indicated one receptor was associated with successfully clearing a virus in experiments.
Digital Editor
|
9.18.2017
10:35am
Another pharmaceutical company revealed it would initiate a restructuring strategy designed to cut costs and streamline operations.
Digital Editor
|
9.13.2017
8:53am
A major pharmaceutical company may have an advantage in the competitive lung cancer treatment space. Details of their study were presented at the ESMO 2017...
Digital Editor
|
9.12.2017
8:46am
Data from this study was presented at the European Society for Medical Oncology taking place in Madrid, Spain.
Digital Editor
|
9.12.2017
8:46am
Overall, these total cuts come out to about 8 percent of Eli Lilly’s workforce.
Digital Editor
|
9.8.2017
8:58am
Investors who participated in this financing included existing investors like Medtronic and Boston Scientific.
Digital Editor
|
9.1.2017
8:00am
A team of scientists found a way to create a novel drug delivery system for an array of different conditions.
Digital Editor
|
8.31.2017
8:00am
Researchers presented results from a late stage study named COMPASS at the annual European Society of Cardiology Meeting taking place in Barcelona, Spain.
Digital Editor
|
8.28.2017
11:20am
Advertisement
E.coli carrying the mcr-1 and ndm-5 genes have made it immune to last-resort antibiotics.
Digital Editor
|
8.22.2017
11:25am
Findings from a previous phase IIa proof-of-concept trial indicated the compound is fast-acting and potent across multiple stages of the parasite’s lifecycle.
Digital Editor
|
8.21.2017
10:57am
This news is emblematic of how the development process can be a struggle for these next-gen cancer therapies.
Digital Editor
|
8.16.2017
11:20am
This breakthrough could help wipe the virus off the face of the earth.
Digital Editor
|
8.15.2017
10:09am
The drug is a potent and selective oral kappa opioid receptor being developed as an adjunctive treatment of major depressive disorder and substance use...
Digital Editor
|
8.15.2017
8:35am
Scientists at Arizona State University created the world’s first plant-based Zika vaccine that could be safer, more potent, and more cost-effective to produce...
Digital Editor
|
8.9.2017
10:42am
Investigators will randomize eligible participants into two treatment arms.
Digital Editor
|
8.9.2017
8:55am
Injections of exenatide showed signs of improving movement in Parkinson’s patients over a one year period.
Digital Editor
|
8.8.2017
2:12pm
The de-identified data that emerges from these tests will be analyzed for clues pertaining to how genetics and environmental factors combine to impact brain...
Digital Editor
|
8.4.2017
10:48am
Investigators tested the impact of 50 mg, 100 mg, or 200 mg against placebo on these patients.
Digital Editor
|
8.4.2017
9:58am
The Biden Cancer Initiative was spun off from the Biden Foundation in June 2017.
Digital Editor
|
8.2.2017
8:37am
Achieving these goals would give companies access to certain perks.
Digital Editor
|
8.1.2017
2:29pm
The company presented results from two studies involving potentially groundbreaking drugs.
Digital Editor
|
7.28.2017
9:37am
The firm completed a $42 million funding round aimed at advancing the company’s lead antibiotic candidate deeper into clinical development.
Digital Editor
|
7.27.2017
10:42am
A component of the common spice turmeric could be the key to killing treatment-resistant neuroblastoma tumor cells.
Digital Editor
|
7.26.2017
9:05am
The company’s clinical development program for this drug includes tests for over 30 tumor types in over 500 clinical trials.
Digital Editor
|
7.25.2017
10:43am
Proving this drug’s mechanism of action is viable could ultimately yield a multi-purpose therapy that could work for autoimmune conditions like lupus and...
Digital Editor
|
7.24.2017
1:37pm
Developing a potent therapy for Alzheimer’s disease will be one of the biggest healthcare challenges over the next few decades.
Digital Editor
|
7.21.2017
8:47am